SCHEMBL6316150

SCHEMBL6316150

CCc1ccc(-c2noc(N)c2C(=O)NCCCCc2ccccc2)s1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.51
TSHR P16473 1/20 0.48
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
HPGD P15428 4/20 0.44
ALDH1A1 P00352 3/20 0.44
GFER P55789 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
FAAH O00519 1/20 0.42
USP2 O75604 2/20 0.41
GLA P06280 1/20 0.41
STAT3 P40763 1/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
POLB P06746 2/20 0.40
GAA P10253 2/20 0.40
MAPT P10636 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
HTT P42858 2/20 0.40
HSP90AA1 P07900 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6318063 0.97 L3MBTL1 (0.54) L3MBTL1TSHRNPC1RAB9AHPGD
SCHEMBL6317389 0.93 NPC1 (0.53) L3MBTL1TSHRNPC1RAB9AALDH1A1
SCHEMBL6324861 0.90 L3MBTL1 (0.55) L3MBTL1TSHRNPC1RAB9AHPGD
SCHEMBL6315932 0.88 ALOX15 (0.42) L3MBTL1NPC1RAB9AHPGDALDH1A1
SCHEMBL6318741 0.87 L3MBTL1 (0.49) L3MBTL1TSHRNPC1RAB9AHPGD
SCHEMBL6324338 0.87 CA1 (0.52) L3MBTL1TSHRNPC1RAB9AHPGD
SCHEMBL6315066 0.87 L3MBTL1 (0.59) L3MBTL1TSHRNPC1RAB9AHPGD
SCHEMBL6317695 0.87 ALOX15 (0.43) L3MBTL1HPGDALDH1A1SMN1; SMN2GAA
SCHEMBL6321721 0.87 ALOX15 (0.43) L3MBTL1HPGDALDH1A1SMN1; SMN2GAA
SCHEMBL6316490 0.87 ALOX15 (0.43) L3MBTL1HPGDALDH1A1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 L3MBTL1 4176/4885TSHR 3971/4885NPC1 3741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.